April 14, 2025

FDA Clears Tablet for Cholestatic Pruritus

The FDA has approved a tablet formulation of maralixibat (LIVMARLI) for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.

Conexiant

April 11, 2025

New Models Enhance Colorectal Adenoma Screening

Integrated mathematical modeling provides an effective non-invasive strategy for colorectal adenoma risk stratification, according to the latest study.

Conexiant

April 11, 2025

Early Antibiotics Linked to Asthma, Eczema

Researchers found early-life antibiotic use was linked to increased risk of asthma and eczema, but not most other immune diseases, after adjusting for familial factors.

Conexiant

April 11, 2025

Higher Arsenic in Brown Rice Poses Risk to Children

Research reveals brown rice contains significantly more inorganic arsenic than white rice, with exposure levels potentially exceeding safety thresholds for young children under 5 years old.

Conexiant

April 10, 2025

FDA to Pilot Animal-Free Models

"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use."

Reuters

April 10, 2025

FDA Clears Stapler for Single-Port Surgery

The FDA has cleared Intuitive’s SP SureForm 45 stapler, the first stapler designed for single-port robotic surgery using the da Vinci SP system.

Conexiant

April 09, 2025

Oral Microbiome Linked to Chronic Pain in Women

Study finds poor oral health and oral pathobionts associated with pain in migraine, fibromyalgia, and abdominal disorders, suggesting possible treatment avenues.

Conexiant

April 09, 2025

Dual Immunotherapy Approved for Advanced CRC

The FDA approved nivolumab with ipilimumab for unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer.

Conexiant

April 09, 2025

Citrus Intake Linked to Lower Depression Risk

Citrus intake was prospectively associated with a decreased risk of depression, according to a recent study.

Conexiant